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INTRODUCTION 
Clinical	  inves+ga+on	  has	  revealed	  a	  subgroup	  of	  head	  and	  neck	  cancers	  that	  are	  virally	  
mediated.	  	  The	  rela+onship	  between	  nasopharyngeal	  cancer	  and	  Epstein	  Barr	  Virus	  (EBV)	  has	  
long	  been	  established	  and	  an	  associa+on	  between	  oropharyngeal	  cancer	  and	  Human	  
Papillomavirus	  (HPV)	  has	  been	  discovered1,2.	  	  These	  cancers	  oFen	  present	  with	  nodal	  
involvement	  and	  generally	  respond	  well	  to	  radia+on	  treatment,	  evidenced	  by	  tumour	  
regression1	  (Figure	  1).	  	  This	  results	  in	  the	  need	  for	  treatment	  plan	  adapta+on	  or	  re-­‐planning	  in	  a	  
subset	  of	  pa+ents.	  Adap+ve	  techniques	  allow	  the	  target	  region	  of	  the	  radiotherapy	  treatment	  
plan	  to	  be	  altered	  in	  accordance	  with	  treatment-­‐induced	  changes	  to	  ensure	  that	  under	  or	  over	  
dosing	  does	  not	  occur3.	  We	  sought	  to	  iden+fy	  poten+al	  risk	  profiles	  based	  on	  nodal	  size	  to	  be	  
evaluated	  in	  a	  future	  prospec+ve	  adap+ve	  radiotherapy	  trial.	  	  
Figure	  1	  	  Radiotherapy	  treatment	  
response	  of	  pa+ent	  with	  HPV	  posi+ve	  
head	  and	  neck	  cancer	  with	  advanced	  
nodal	  disease	  
Planning CT scan 
CT scan after 
19# of treatment 
METHODS 
Between	  2005-­‐2010,	  121	  pa+ents	  with	  virally	  mediated,	  node	  posi+ve	  nasopharyngeal	  (EBV	  
posi+ve)	  or	  oropharyngeal	  (HPV	  posi+ve)	  cancers,	  receiving	  cura+ve	  intent	  radiotherapy	  
treatment	  were	  reviewed.	  	  Pa+ents	  were	  analysed	  based	  on	  maximum	  size	  of	  the	  dominant	  
node	  at	  diagnosis	  with	  a	  view	  to	  grouping	  them	  in	  varying	  risk	  categories	  to	  determine	  the	  need	  
of	  re-­‐planning.	  Pa+ents	  who	  underwent	  a	  re-­‐planning	  scan	  were	  further	  inves+gated	  to	  
determine	  other	  factors	  including	  magnitude	  of	  weight	  loss	  and	  primary	  tumour	  and	  nodal	  
tumour	  regression.	  	  The	  frequency	  and	  +ming	  of	  the	  re-­‐planning	  scans	  was	  also	  evaluated.	  
RESULTS 
Selected	  characteris+cs	  of	  the	  pa+ent	  cohort	  is	  demonstrated	  in	  Table	  1.	  	  
•  16	  nasopharyngeal	  and	  105	  oropharyngeal	  tumours	  were	  reviewed	  	  
•  25	  (21%)	  pa+ents	  underwent	  re-­‐planning	  CT	  at	  a	  median	  of	  22	  (range,	  0-­‐29)	  frac+ons	  
	  
Figure	  2	  displays	  the	  pre-­‐treatment	  nodal	  size	  as	  a	  comparison	  of	  re-­‐planning	  scan	  (re-­‐CT)	  
status.	  	  Two	  pa+ents	  (one	  re-­‐CT	  and	  one	  non	  re-­‐CT)	  were	  excluded	  from	  this	  analysis	  due	  to	  
their	  nodal	  sizes	  lying	  greater	  than	  4	  standard	  devia+ons	  outside	  the	  mean.	  	  Specific	  
informa+on	  rela+ng	  to	  those	  pa+ents	  who	  underwent	  a	  re-­‐planning	  scan	  is	  described	  in	  
Table	  2.	  
	  	  
Based	  on	  the	  analysis,	  pa+ents	  were	  subsequently	  placed	  into	  risk	  categories	  based	  on	  pre-­‐
treatment	  nodal	  size:	  	  
•  Group	  1	  -­‐	  ≤35mm	  	  
•  Group	  2	  -­‐	  36-­‐45mm	  	  
•  Group	  3	  -­‐	  ≥46mm	  	  
	  
Applying	  these	  risk	  categories	  to	  the	  pa+ent	  cohort,	  re-­‐planning	  CT’s	  were	  performed	  in:	  	  
•  Group	  1-­‐	  8/68	  (11.8%)	  
•  Group	  2-­‐	  4/28	  (14.3%)	  
•  Group	  3-­‐	  13/25	  (52%)	  
STATISTICS 
The	  data	  collected	  from	  this	  study	  was	  analysed	  using	  the	  Stata	  program	  to	  iden+fy	  the	  
factors	  that	  may	  contribute	  to	  the	  need	  for	  pa+ents	  to	  undergo	  a	  re-­‐planning	  scan.	  	  	  
Sta+s+cal	  analysis	  included	  basic	  descrip+ve	  sta+s+cs	  and	  logis+c	  regression	  to	  determine	  the	  
rela+ve	  contribu+on	  of	  factors	  such	  as	  nodal	  size	  and	  +ming	  of	  interven+ons.	  	  




Age mean (range) 54 (22-81) 







Nodal size mean 
(range) 





Table	  1	  	  Selected	  pa+ent	  characteris+cs	  
Figure	  2	  	  Box	  and	  whisker	  plot	  demonstra+ng	  nodal	  size	  as	  a	  
func+on	  of	  re-­‐CT	  status	  
CHARACTERISTIC NUMBER 
Mean initial weight 
(kg) 
82.8 
Mean weight at re-
CT (kg) 
76.9 







Mean nodal tumour 
reduction (%) 
38.5 





In	  this	  series,	  pa+ents	  with	  virally	  mediated	  head	  and	  neck	  cancer	  and	  nodal	  size	  >	  46mm	  
appear	  to	  be	  a	  high-­‐risk	  group	  for	  the	  need	  of	  re-­‐planning	  during	  a	  course	  of	  cura+ve	  
radiotherapy.	  This	  finding	  will	  now	  be	  tested	  in	  a	  prospec+ve	  adap+ve	  radiotherapy	  study.	  	  	  
REAL WORLD IMPLICATIONS 
This	  research	  iden+fies	  predic+ve	  factors	  for	  those	  pa+ents	  with	  virally	  mediated	  head	  and	  
neck	  cancer	  that	  will	  benefit	  most	  from	  treatment	  adapta+on.	  	  This	  will	  assist	  in	  minimising	  
the	  side	  effects	  experienced	  by	  these	  pa+ents	  thereby	  improving	  their	  quality	  of	  life	  aFer	  
treatment.	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